Application of botulinum toxin to the management of neurogenic inflammatory disorders
US6063768A · kind A · utility
263Cited by
5References
6Claims
0Family size
Inventor
Key dates
| Filing date | Sep 4, 1997 |
| Grant date | May 16, 2000 |
| Priority date | — |
| Expiry date | Sep 4, 2017 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S435/842
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a method for the use of at least one serotype or a combination of serotypes of Botulinum neurotoxin either alone or in combination with other peptides or fusion proteins, that when administered in a safe and effective amount, antagonize and therefore decrease or block inflammation induced by the neurogenic mechanisms underlying or associated with inflammatory disorders, in particular, arthritis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.